Neonatal Respiratory Distress Syndrome Treatment Market Study Highlights How Industry Demand Is Evolving

The treatment market for neonatal respiratory distress syndrome (RDS) is poised for significant expansion as healthcare innovations and increasing awareness continue to drive demand. This sector is evolving rapidly, with new technologies and therapies improving outcomes for newborns facing respiratory challenges. Below is an overview of the market size, key players, emerging trends, and segment forecasts shaping this critical healthcare field.

Projected Growth Outlook for the Neonatal Respiratory Distress Syndrome Treatment Market
The neonatal respiratory distress syndrome treatment market is expected to reach $1.5 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.8%. This anticipated growth is fueled by advancements in synthetic surfactant therapies, the widespread adoption of non-invasive ventilation techniques, increased investments in neonatal care equipment, and the modernization of hospital respiratory support systems. In addition, rising global awareness about neonatal health complications and improved management of premature births are stimulating market expansion. Key trends that will continue to influence this market include the rising use of surfactant replacement therapies, enhanced neonatal intensive care infrastructure, and the development of novel synthetic and bioengineered surfactants.

The neonatal respiratory distress syndrome treatment market size has grown strongly in recent years. It will grow from $1.03 billion in 2025 to $1.11 billion in 2026 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to high premature birth rates, reliance on conventional oxygen therapy, limited access to neonatal intensive care units, early adoption of natural surfactants, increasing infant respiratory morbidity.

Download a free sample of the neonatal respiratory distress syndrome treatment market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20899&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Prominent Players Leading the Neonatal Respiratory Distress Syndrome Treatment Market
Several major corporations are actively shaping the neonatal respiratory distress syndrome treatment market. These include Medtronic Plc, GE Healthcare, Koninklijke Philips NV, Drägerwerk AG & Co. KGaA, Chiesi Farmaceutici, Fisher & Paykel Healthcare, Vyaire Medical, Laerdal Medical, Hamilton Medical, Inspiration Healthcare, Ventec Life Systems, Neotech Products, Windtree Therapeutics Inc., Discovery Laboratories Inc., ResMed Inc., Abbott Laboratories, Aerogen Pharma Corp., ONY Biotech, Yuhan Corporation, Atom Medical Corporation, Mindray Bio-Medical Electronics, Getinge AB, Nihon Kohden Corporation, and Siare Engineering Spa.

In a notable development, Chiesi Group partnered with Oak Hill Bio in January 2024 with the goal of advancing neonatal treatments. This collaboration is centered around OHB-607, a novel therapy aimed at preventing severe bronchopulmonary dysplasia (BPD) and its long-term respiratory consequences in preterm infants, particularly those born before 28 weeks gestation with low IGF-1 levels. Oak Hill Bio, based in the UK, focuses on therapies for neonatal and rare diseases.

View the full neonatal respiratory distress syndrome treatment market report:
https://www.thebusinessresearchcompany.com/report/neonatal-respiratory-distress-syndrome-treatment-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends Offering New Directions in Neonatal Respiratory Distress Syndrome Treatment
Leading companies in this space are focusing on next-generation technologies like portable nitric oxide delivery systems to enhance treatment accessibility and effectiveness. These systems improve oxygenation and reduce complications while allowing safe use beyond traditional neonatal intensive care units (NICUs). Portable nitric oxide devices generate and deliver inhaled nitric oxide on demand, helping to alleviate pulmonary hypertension in neonates with hypoxic respiratory failure and enabling treatment during patient transfers.

For example, Beyond Air Inc., a US medical device firm, submitted a PMA supplement to the U.S. FDA in June 2025 for LungFit PH 2, a lightweight, transport-ready nitric oxide generator that uses patented Ionizer technology. This device emphasizes portability and safety by providing continuous nitric oxide delivery with minimal nitrogen dioxide production, crucial during neonatal transport. Simultaneously, phase-4 registry data for INOmax, a long-established inhaled nitric oxide therapy by Mallinckrodt, continue to demonstrate its real-world effectiveness in managing pulmonary hypertension in newborns, highlighting the ongoing clinical relevance of inhaled nitric oxide treatments.

Segmentation and Market Share Forecasts in Neonatal Respiratory Distress Syndrome Treatment
The neonatal respiratory distress syndrome treatment market is divided into several key segments:
1) Therapy types including Oxygen Therapy and Surfactant Therapy
2) Routes of administration, which cover Parenteral, Inhalation, and other methods
3) End users such as Hospitals, Sub-Acute Facilities, Home Care settings, and Retail Pharmacies

Within these categories, further subdivisions exist:
- Oxygen Therapy is broken down into Conventional Oxygen Therapy, High-Flow Nasal Cannula (HFNC) Oxygen Therapy, Continuous Positive Airway Pressure (CPAP) Oxygen Therapy, and Invasive Mechanical Ventilation with Oxygen Therapy.
- Surfactant Therapy includes Natural Surfactants, Synthetic Surfactants, Combined Surfactant Therapy (both natural and synthetic), Prophylactic Surfactant Therapy, and Rescue Surfactant Therapy.

This detailed segmentation helps stakeholders better understand the market's structure and identify specific areas for growth and investment within neonatal respiratory distress syndrome treatment.

Expanded capabilities in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.